Hospital Clínico San Carlos (Spain) Hospital Son Llatzer (Spain) Hospital Universitario Doce de Octubre (Spain) Hospital del Mar (Spain) Hospital Universitario Insular de Gran Canaria (Spain) Institut Català d'Oncologia Badalona (ICO) (Spain) Hospital Quiron San Camilo-Ruber Juan Bravo (Spain) Hospital Universitario Ramón y Cajal (Spain) Institut Català d'Oncologia L'Hospitalet (ICO) (Spain) Hospital Universitario Miguel Servet (Spain) Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona (Spain) Consorci Hospital General Universitari de València (Spain) Hospital Clínico Universitario de Valencia (Spain) Hospital Universitario Reina Sofía (Spain) Instituto Valenciano de Oncología (IVO) (Spain) Hospital Universitario Virgen del Rocío (Spain) MD Anderson Cancer Center Madrid (Spain) Hospital San Pedro de Alcántara (Spain) Hospital Da Luz Lisboa (Portugal) Hospital Fernando da Fonseca (Portugal) Hospital de Santa Maria - Centro Hospitalar Lisboa Norte (Portugal) Instituto Portugues Oncologia de Porto (IPO) (Portugal) Champalimaud Clinical Centre (Portugal)

Dr. Cortes and Dr. Llombart PHERain interview

Beyond Chemotherapy

Dr. Vanes Quiroga

Dr. Sofia Braga

Dr. Silvi Antolín

Dr. Escrivá de Romaní

Dr. Philipp Aftimos

Dr. Manuel Ruiz

Prof. Daniele Generali PHEGain interview

Dr. Jacques Medioni

Dr. Dunca Wheatley

DEBBRAH

A MULTICENTER, OPEN-LABEL, SINGLE-ARM, MULTICOHORT PHASE II CLINICAL TRIAL OF TRASTUZUMAB DERUXTECAN (DS-8201A) IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 EXPRESSING METASTATIC BREAST CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

CLINICAL TRIAL DETAILS

TRIAL OVERVIEW

PRESS RELEASE

SCIENTIFIC IMPACT

BLOG ARTICLES RELATED

TRIAL SITES

TRIAL RESUME